Key Points

Revolution Medicines aims to replace chemotherapy with targeted treatments.
Its positive Phase 3 findings could pave the way towards its regulatory approval.
Its growth potential is drawing in big investors like Stanley Druckenmiller.

Revolution Medicines (NASDAQ: RVMD) aims to replace chemotherapy for some of the most aggressive cancers with its targeted treatments. It directly targets the RAS protein - which feeds the growth of non-small cell lung, pancreatic, and colorectal cancers - by shutting down the hyperactive cellular signals that drive their spread.

Revolution has not generated any revenue, and its flagship treatment, Daraxonrasib, has not been approved by the FDA yet. However, positive results from its Phase 3 trial, which nearly doubled the survival rate of patients with previously treated metastatic pancreatic cancer, prompted the FDA to grant it Breakthrough Therapy and Orphan Drug designations.

It is also nearly completed its New Drug Application (NDA) to the FDA. The European Medicines Agency (EMA) launched an accelerated review of daraxonrasib this month, putting it on track for a global launch.

Stanley Druckenmiller backs the high-flying stock

Revolution stock has already risen 125% this year in anticipation of Daraxonrasib regulatory approvals, but it still has some big backers. In the first quarter of 2026, Stanley Druckenmiller Duquesne Family Office bought 316,000 shares of Revolution Medicines.

That stake, which was worth $30.6 million at the time of its 13F filing, is now worth $56.6 million. That only accounts for 1%-2% of its equity portfolio, but it is a pretty strong vote of confidence in a pre-revenue biotech company. Revolution is still a speculative biotech play, but it could attract much more attention if its bold bet to replace chemotherapy pays off.

Should you buy stock in Revolution Medicines right now?

Before you buy stock in Revolution Medicines, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now and Revolution Medicines was not one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004 if you invested $1,000 at the time of our recommendation, you would have $397,351! Or when Nvidia made this list on April 15, 2005 if you invested $1,000 at the time of our recommendation, you would have $1,304,257!

Now, it is worth noting Stock Advisor total average return is 934% - a market-crushing outperformance compared to 210% for the S&P 500. Do not miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

Stock Advisor returns as of July 17, 2026.